The company plans to launch the new system, utilizing its Kaleido patch pump, in Germany and the Netherlands in early 2026. Launch plans come on the heels of CE mark approval for Diabeloop’s DBLG2 algorithm, which will be paired with Kaleido. The Kaleido pump initially won CE mark back in October 2024.
Combining Kaleido and DBLG2 enables automated insulin delivery controlled directly from the user’s smartphone. The system also utilizes the Dexcom G7 continuous glucose monitor (CGM) to complete the closed loop. Kaleido previously worked as part of an automated insulin delivery system that used the previous-generation Dexcom G6.
Kaleido offers users options in terms of wearability and comes with two durable, rechargeable pumps, eliminating the need to dispose of the pump every three days, while the infusion set lasts for that three-day span. The design aims to integrate seamlessly into the user’s daily life.
Users can choose between a short tube for placement as a patch directly on the body or a longer tube for carrying the pump in the pocket. They can pause or take the pump off for intermittent breaks, too.
Utrecht, The Netherlands-based ViCentra plans to work with Diabeloop to begin rolling out the new system in the fall. During pre-launch, they intend to gather real-world experience data ahead of a full launch with G7 integration in early 2026.
“Kaleido is built for people, not just glucose levels,” said Tom Arnold, CEO of ViCentra. “This launch marks a step-change in wearable diabetes technology: beautifully designed, smartphone-controlled, and powered by a proven algorithm. Together with our partners, we’re making flexible, closed-loop therapy more accessible—and more human.”
